Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...
Cystatin C (CysC) is an independent risk factor for adverse outcomes in patients with HF across the ejection fraction (EF) spectrum.
A tradition at the HFSA meetings, the Hyde Park sessions give presenters, "unfettered by the usual standards of peer review," a chance to present or stimulate ideas that "may or may not be supported ...
EAT index measured by CMR may identify high-risk HFpEF patients and predict outcomes. Learn more about its role in risk ...
Please provide your email address to receive an email when new articles are posted on . Finerenone reduced risk for CV death and worsening heart failure vs. placebo in this patient population. Pooled ...
2d
Distinct metabolic signature found in patients with heart failure with preserved ejection fraction
What exactly happens in the hearts of patients with heart failure with preserved ejection fraction (HFpEF)—and how can this ...
고도 비만을 동반한 심부전 환자는 심장 근육이 약해지는 것으로 나타났다. 체중을 줄이면 약화된 근육이 회복된다는 점도 확인됐다. 새로운 심부전 치료제를 개발할 단서를 제시했다는 평가가 나온다. 데이비드 카스 미국 존스홉킨스대 의대 심장학과 교수 연구팀은 고도 비만을 동반한 '박출률 보존 심부전'(HFpEF) 환자를 대상으로 심장 근육 생체검사를 시행해 비만 ...
Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results